University of Plymouth   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Plymouth United Kingdom (1862)

Organization Overview

First Clinical Trial
2000
NCT01062867
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Clinical Lecturer (University of Plymouth) and Honorary Consultant Neurologist, Plymouth Hospitals NHS Trust. | Derriford Hospital | Peninsula Medical School, University of Plymouth, UK | Plymouth Hospitals NHS Trust | Plymouth University Peninsula Schools of Medicine and Dentistry | Salisbury Clinic - Plymouth - UK | Salisbury Clinic, Plymouth, UK | University of Plymouth

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dyskinesias (Phase 2)

Erectile Dysfunction (Phase 3)

Hypogonadism (Phase 3)

Lymphoma (Phase 3)

Lymphoma, Mantle-Cell (Phase 3)

Multiple Sclerosis (Phase 3)

Muscle Spasticity (Phase 3)

Parkinson Disease (Phase 2)

Sclerosis (Phase 3)

Sepsis (Phase 4)

Toxemia (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 15
  • # of Trial APIs: 27